Eli Lilly moved to bulk up its infectious-disease pipeline, agreeing to acquire three companies in deals totaling up to $3.8 billion. The acquisitions target viral and bacterial pathogen R&D and add specialized platforms intended to broaden Lilly’s exposure beyond its existing portfolio. The company’s infectious-disease shopping spree builds on its broader M&A push, positioning Lilly to pursue both earlier-stage biology and later development assets. Financial terms were structured around deal values up to the stated ceiling, with the specific acquisition targets covering complementary areas across pathogen discovery and development. For the biotech market, the deal underscores continued scale investing by Big Pharma in infectious disease, even as development costs remain elevated and competitive landscapes intensify. It also signals that Lilly sees sufficient pipeline density to justify multiple simultaneous platform add-ons rather than single-asset purchases.